Vaxil Bio Ltd. is a biotechnology company engaged in the development of signal peptide-based immunotherapies for the treatment of cancer and infectious diseases. Its pipeline consists of ImMucin, SPmAb2, SPmAb6, and MTbuVax. The company was founded on July 26, 2006 and is headquartered in Toronto, Canada.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Vaxil Bio Ltd. market cap is $108,000.00.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Vaxil Bio Ltd. 52 week high is $0.50 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Vaxil Bio Ltd. 52 week low is $0.011 as of November 22, 2026.
Vaxil Bio Ltd. stock price today is $0.0271.
Vaxil Bio Ltd. stock price yesterday was $0.0797.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Vaxil Bio Ltd.'s P/E ratio is 0.4.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Vaxil Bio Ltd. P/B ratio is 0.1283.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Vaxil Bio Ltd. 50-day moving average is $0.0388.